Cytokine Signalling Forum

Publications




Comparative efficacy and safety of secukinumab, ixekizumab, and tofacitinib in patients with active psoriatic arthritis showing insufficient response to tumor necrosis factor inhibitors

Song GG, Lee YH. - Int J Clin Pharmacol Ther. 2021. Epub ahead of print.

Bayesian network meta-analysis of randomised controlled trials (RCTs) highlights the effectiveness of secukinumab, ixekizumab, and tofacitinib in patients with psoriatic arthritis (PsA) and an inadequate response to tumour necrosis factor inhibitors (TNFi).

There is a current need for therapies with alternative mechanisms of actions to DMARDs and TNFi, for the significant proportion of patients with PsA who insufficiently respond to these therapies.

While RCTs for therapies such as secukinumab and ixekizumab (IL-17 inhibitors), and tofacitinib (JAK inhibitor) highlight their effectiveness in this patient group, compared with placebo, a lack of head-to-head comparisons means it is more difficult to determine their efficacy and safety.

To this end, Song, et al. carried out a network meta-analysis to examine the relative efficacy and safety of secukinumab, ixekizumab, and tofacitinib in patients with active PsA and an inadequate response to TNFi.